Details for Patent: 8,022,054
Which drugs does patent 8,022,054 protect, and when does it expire?
Patent 8,022,054 protects ZTALMY and is included in one NDA.
This patent has twenty-four patent family members in fourteen countries.
Summary for Patent: 8,022,054
| Title: | Liquid ganaxolone formulations and methods for the making and use thereof | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Kenneth Shaw, Mingbao Zhang | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Immedica Pharma US Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US11/605,700 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,022,054 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Formulation; Compound; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 8,022,054: Ganaxolone Aqueous Dispersion Claims and Patent LandscapeU.S. Patent No. 8,022,054 claims a stabilized aqueous dispersion of nanoparticulate ganaxolone. The central legal requirements are a hydrophilic polymer, wetting agent, qualifying low-molecular-weight aromatic complexing agent, dual-preservative system, and ganaxolone particles with a volume-weighted median diameter of 50 to 500 nm. The claims also cover particle-growth control, gastrointestinal dispersion behavior, storage stability, composition ranges, pharmacokinetic performance, and a 50 mg/mL formulation. The broadest claim is composition claim 1. The dependent claims progressively narrow the formulation through excipient identity, concentration, particle size, stability testing, processing endpoint, preservative selection, and clinical pharmacokinetic outcomes. The patent is therefore most relevant to liquid oral ganaxolone products using a nanoparticle suspension rather than to ganaxolone generally. What does U.S. Patent 8,022,054 protect?Claim 1 requires all of the following elements:
The claim is cumulative. A formulation that contains ganaxolone, a polymer, and a wetting agent but lacks the claimed complexing agent or dual-preservative system would not satisfy claim 1 as written. The claim also uses functional language. The complexing agent must stabilize particle growth after an initial growth period and endpoint. The formulation must contain the agent in an amount that performs that function. Particle size alone is insufficient. How broad is the independent composition claim?Claim 1 is chemically broad but formulation-specific. The complexing-agent definition includes at least three structural classes:
The claim imposes a molecular-weight ceiling of less than 550. The dependent claims identify methylparaben, propylparaben, benzoic acid, pharmaceutically acceptable salts, mixtures, and methyl anthranilate as examples. The claim does not require a particular hydrophilic polymer, wetting agent, preservative, salt, sweetener, or ganaxolone concentration. Those limitations appear in dependent claims. A competing product could therefore avoid many dependent claims while remaining within claim 1 if it retains the required core elements. The most important breadth issue is the relationship between the particle-stabilization function and the claimed excipient classes. A formulation may contain a qualifying aromatic compound, but infringement would likely depend on whether the compound actually performs the claimed particle-growth stabilization function at the claimed concentration. What formulations are protected by the dependent claims?Polymer and wetting-agent limitationsClaims 2 and 3 define broad concentration ranges:
Claims 13 to 17 identify cellulosic and vinyl polymers. The specified examples include cellulose ethers, hydroxypropylmethylcellulose, vinyl pyrrolidone/vinyl acetate copolymer S630, and polyvinyl alcohol. Claims 19 identifies sodium lauryl sulfate, pharmaceutically acceptable docusate salts, and mixtures as wetting agents. Particle-size limitationsThe principal particle-size range is 50 to 500 nm under claim 1. The dependent ranges narrow the target:
These claims concern volume-weighted median diameter, not merely a mean or number-weighted average. Measurement method, sample preparation, dispersion conditions, and instrument settings could become material in an infringement or validity dispute. Preservative limitationsClaim 1 requires at least two preservatives. Claim 51 lists:
The claim language appears to permit any combination of at least two qualifying preservatives, subject to the requirement that the amount be sufficient to inhibit microbial growth. A formulation using one preservative, or a nonlisted preservative combination, would require separate analysis under the broader wording of claim 1. When does the patent claim particle-growth stability?Claims 4 to 8 require that D50 change by no more than approximately 15% after storage at room temperature for:
Claims 27 and 28 add accelerated thermal stability:
Claim 29 addresses simulated gastric and intestinal conditions. It requires a D50 increase of no more than approximately 150% after one hour at 36°C to 38°C in SGF or SIF at a ganaxolone concentration of 0.5 to 1 mg/mL. These limitations create evidentiary issues. A product may have the same nominal composition but fall outside a stability claim if its measured D50 changes beyond the specified threshold. Conversely, a stability claim may be difficult to enforce without a defined baseline, analytical protocol, storage humidity, vial configuration, and particle-size methodology. What endpoint and complexing agents are protected?Claims 32 to 36 tie the complexing agent to the particle-growth endpoint:
Claim 35 is particularly narrow because it combines a specific complexing agent with a defined endpoint. Claim 36 does the same for benzoic acid. The patent’s technical concept is not simply adding a preservative to an oral suspension. It is using selected aromatic small molecules to control post-milling or post-dispersion particle growth after an initial growth phase. That functional distinction is central to both infringement analysis and validity analysis. What pharmacokinetic outcomes are claimed?Claims 44 to 50 protect formulations by pharmacokinetic performance in adult subjects. The relevant limitations include:
These are product-by-process-adjacent limitations expressed through clinical performance. They may create a substantial enforcement burden because infringement would require demonstrating that the accused formulation produces the claimed pharmacokinetic result under comparable dose, fed-state, fasted-state, population, sampling, and statistical conditions. The claims do not necessarily require a particular commercial label or indication. A formulation used for a different indication could still implicate the composition claims if the structural and functional requirements are met. What is the commercial relevance to ZTALMY?Ganaxolone is marketed in the United States as ZTALMY, an oral suspension approved by the FDA for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients two years of age and older. The product is an aqueous oral suspension containing 50 mg/mL ganaxolone, making claims 43 and 51 commercially relevant to the marketed dosage form.[2] The FDA-approved product contains excipients that should be compared against the patent claim limitations, including the identity and concentration of the polymer, wetting agent, preservatives, sweetener, and any aromatic complexing agent. The presence of a 50 mg/mL concentration alone does not establish coverage because claim 43 depends on the broader formulation requirements of claim 1. The principal product-level risk questions are:
What is the Orange Book status of U.S. Patent 8,022,054?FDA Orange Book coverage must be determined from the current Approved Drug Products with Therapeutic Equivalence Evaluations database and the relevant ZTALMY listing. A patent’s existence does not establish that it is listed for a specific approved product. For Hatch-Waxman purposes, an Orange Book-listed patent may support a Paragraph IV certification by an abbreviated new drug application applicant. A patent that is not listed generally does not create the same statutory notice and 30-month-stay framework, although it may remain enforceable in separate patent litigation. The patent’s claims are composition claims rather than only method-of-use claims. If listed against an approved ganaxolone oral suspension, it would be more significant to generic applicants than a patent limited to an indication or dosing method. The decisive commercial issues are the current listing status, listed expiration date, any pediatric exclusivity adjustment, and whether the patent remains enforceable. When does U.S. Patent 8,022,054 lose exclusivity?U.S. patent term generally runs for 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable transitional rules.[3] The issue date, September 20, 2011, does not by itself determine expiration. The relevant term analysis is:
A definitive expiration date requires the official USPTO continuity and Patent Center records, the front-page patent-term-adjustment calculation, and any terminal disclaimer or regulatory extension record. The supplied claim text alone does not establish those dates. Which companies are challenging the patent?No Paragraph IV challenger, ANDA litigation, settlement agreement, or district-court case can be identified from the claim text. A reliable challenger analysis requires a current search of:
The absence of a challenger in the supplied material should not be treated as evidence that no challenge exists. How strong is the patent estate?The patent has meaningful technical specificity but mixed enforcement breadth. Strengths
Vulnerabilities
How does this patent compare with later ganaxolone patents?U.S. Patent 8,022,054 should be separated from later patents directed to:
An applicant designing around this patent could target a formulation that changes one or more required elements, such as:
Design-around success would depend on the doctrine of equivalents, prosecution-history estoppel, and the exact scope of any continuation or related patent family. What manufacturing and geographic barriers remain?The patent is a U.S. right. Corresponding foreign applications, national-phase patents, continuations, and divisionals must be reviewed separately for Europe, Japan, Canada, Australia, and other commercial markets. Manufacturing barriers may arise from the need to reproduce:
A process can be commercially difficult to reproduce without being literally claimed. Conversely, a manufacturing process may infringe a related process patent even if the resulting formulation avoids claim 1 of this patent. Key Takeaways
FAQs About U.S. Patent 8,022,054Does U.S. Patent 8,022,054 cover all ganaxolone products?No. Its claims are directed to a specific aqueous nanoparticulate dispersion architecture and require multiple excipient, particle-size, stabilization, and preservation limitations. Does a 50 mg/mL ganaxolone suspension automatically infringe?No. Claim 43 depends on claim 1. The product must also satisfy the claim 1 requirements, including particle size, complexing agent, particle-growth stabilization, hydrophilic polymer, wetting agent, and dual-preservative system. Can a generic avoid the patent by using a different preservative?Potentially, if the alternative formulation does not contain at least two preservatives within the scope of claim 1 and does not meet the remaining claim elements. The complete formulation and equivalents analysis controls. Are the pharmacokinetic claims likely to be important in ANDA litigation?They can be relevant, but they may be harder to prove than composition claims because infringement depends on clinical performance under defined fed, fasted, dose, sampling, and steady-state conditions. Does patent expiration eliminate FDA exclusivity?No. Patent term and FDA regulatory exclusivity are separate rights. NCE, orphan-drug, pediatric, and other exclusivity periods can continue after a patent expires, while a patent can expire before regulatory exclusivity ends. References
More… ↓ |
Drugs Protected by US Patent 8,022,054
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immedica Pharma | ZTALMY | ganaxolone | SUSPENSION;ORAL | 215904-001 | Jun 1, 2022 | RX | Yes | Yes | 8,022,054 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,022,054
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1959966 | ⤷ Start Trial | 122024000005 | Germany | ⤷ Start Trial |
| European Patent Office | 1959966 | ⤷ Start Trial | C202430002 | Spain | ⤷ Start Trial |
| African Regional IP Organization (ARIPO) | 3071 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
